Armed CAR-T cells to better fight cancer
2022-04-04
Immunotherapy is increasingly becoming a successful way to treat cancer. Researchers at IGP have now developed armed CAR-T cells that reinforce the immune defence against cancer and that could increase the possibilities to successfully treat solid tumours. The study has been published in the journal Nature BioMedical Engineering.
The use of immunotherapy to treat cancer is increasing and genetically modified immune cells called CAR-T cells are efficacious for treating blood cancer. Unfortunately, their efficiency is impaired in solid tumours due to local immune suppression in the tumour.
To avoid this problem, the IGP researchers have armed CAR-T cells by introducing a gene that encodes the immune stimulatory protein NAP (neutrophil-activating protein) from the bacteria Helicobacter pylori. When NAP is released from the CAR-T cells this creates a proinflammatory environment which directly combats the immunosuppressive microenvironment in solid tumors and strengthens the function of the CAR-T cells.
“We believe that this new technology to arm CAR-T cells has the potential to completely change CAR-T cell treatment. NAP, secreted from the armed CAR-T cells can revert the tumours from immunologically ‘cold’ to ‘hot’. In addition, NAP can also recruit other types of immune cells that can attack the tumour cells that are not recognised by the CAR-T cells,” says Di Yu, who has led the study together with Magnus Essand.
To investigate the effect of CAR(NAP)-T cells, the researchers treated mice with different types of tumours and saw that tumour growth was reduced. The survival also increased compared to when CAR-T cells without NAP were used. The researchers also studied human CAR(NAP)-T cells in in vitro experiments and found that they had a better immunostimulatory capacity that conventional human CAR-T cells.
“We have a strong tradition with CAR-T cell treatment of cancer in Uppsala, with Gunilla Enblad and Angelica Loskog treating the first patients in Europe back in 2014. Two academic trials, with in total 39 treated patients, have been performed at Uppsala University Hospital. Based on the strong results in our Nature Biomedical Engineering paper, we are now planning for a clinical trial with our new armed CAR-T cells. We hope to treat the first patient by the end of this year,“ says Magnus Essand.
The upcoming clinical trial has received financial support from Cancerfonden, Vinnova and Elicera Therapeutics.
Elicera Therapeutics was formed by Uppsala University researchers Di Yu and Magnus Essand in order to bring their inventions into clinical trials with the aim to help cancer patients. Uppsala University and Elicera Therapeutics have agreements that Elicera should try to develop these inventions in to medicinal products.
More information:
Paper in Nature Biomedical Engineering
Di Yu’s and Magnus Essand’s research
Elicera
Watch a short video about the research. (1:43 min): https://www.youtube.com/watch?v=pU04RGP5mXA
Short video from Elicera Therapeutics who develops the invention into medicinal products. (2:24): https://www.youtube.com/watch?v=Oq2BapwRQF8
-
Rare genetic variants are not the main cause of common diseases
2022-05-13
Although some rare variants can significantly increase the risk of disease for a few individuals, the majority of the genetic contribution to common diseases is due to a combination of many common genetic variants with small effects. This is shown by researchers at IGP and other departments at Uppsala University in a new comprehensive study published in the journal Nature Communications.
-
Subgroups of brain tumours associated with cell origin and disease prognosis
2022-04-25
Researchers at IGP have detected different subgroups of the brain tumour form glioblastoma, where the cancer cells’ properties depend on which cell type they originate from. The used analysis method could also separate glioblastoma patients with significant differences in survival. The findings open up for identifying specific therapeutic targets for the new subgroups of glioblastoma.
-
Armed CAR-T cells to better fight cancer
2022-04-04
Immunotherapy is increasingly becoming a successful way to treat cancer. Researchers at IGP have now developed armed CAR-T cells that reinforce the immune defence against cancer and that could increase the possibilities to successfully treat solid tumours. The study has been published in the journal Nature BioMedical Engineering.
-
Inflammation and net-like protein structures in cerebral cavernous malformations
2022-03-28
In the condition known as cavernoma, lesions arise in a cluster of blood vessels in the brain, spinal cord or retina. Researchers at IGP now show in a new study that white blood cells and protein structures associated with the immune response infiltrate the vessel lesions. The findings support that inflammation has a role in the development of cavernoma and indicate a potential biomarker for the disease.
-
Protein landscape on cancer cells mapped with new technology
2022-03-03
In recent years, great advances have been made in the development of new, successful immunotherapies to treat cancer. Two types of targeted immunotherapies that have revolutionised areas of cancer care are CAR T-cell therapy and antibody treatments. However, there are still significant challenges in the identification of cancer cell surface proteins that function as targets for immunotherapies. Mattias Belting, professor at Lund University and senior consultant at Skåne University Hospital, and guest professor at IGP, is well on the way and his group’s findings are now published in the journal PNAS.
-
CRISPR-Cas9 can generate unexpected, heritable mutations
2022-02-03
CRISPR-Cas9, the “genetic scissors”, creates new potential for curing diseases; but treatments must be reliable. In a new study, researchers have discovered that the method can give rise to unforeseen changes in DNA that can be inherited by the next generation. These scientists therefore urge caution and meticulous validation before using CRISPR-Cas9 for medical purposes.
-
New technology to study DNA in archived tissue samples
2022-01-19
Researchers at IGP have developed a technology that allows studies of DNA profiles in archived tissue samples. The technology permits investigators to better understand regulation of gene activity in cancer and precision medicine.
-
New genes associated with relapse of acute myeloid leukemia
2022-01-13
In the blood cancer type acute myeloid leukemia, it is common that patients relapse some time after treatment. Researchers from IGP have in a new study identified genes that seem to be associated with the risk of relapse. The findings may form the basis for new treatment strategies and contribute to better survival for patients with acute myeloid leukemia.